Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 381, Issue 4, pp 285–295

Activation of PPARγ by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats

  • Celine S. Weiss
  • Marco Hagenmüller
  • Martina Pichler
  • Sebastian Münz
  • Marco Ochs
  • Sebastian J. Buss
  • Raffi Bekeredjian
  • Hugo A. Katus
  • Stefan E. Hardt
ORIGINAL ARTICLE

Abstract

Sustained left ventricular hypertrophy (LVH) accelerates cardiac dysfunction and heart failure. Previous reports have suggested that activation of the peroxisome proliferator-activated receptor γ (PPARγ)-dependent pathway is involved in development of cardiac hypertrophy. Thiazolidinediones (TZDs) such as pioglitazone activate PPARγ and are clinically used as antidiabetics. Given inconsistent reports regarding effects of TZDs on LVH, we examined in the present study the influence of pioglitazone on LVH in a rat model of aortic banding. Aortic banding was induced in rats by clipping the ascending aorta. Animals received pioglitazone (3 mg/kg/day) or placebo. Echocardiographic, hemodynamic, histological, and biochemical measurements were performed after 2 and 4 weeks. Pressure gradient was comparable between pioglitazone- and placebo-treated animals after 2 and 4 weeks. Left ventricular function was not different between the groups. In sham as well as in banded animals, LV/body weight ratio was increased in pioglitazone- as compared to placebo-treated animals after 2 and 4 weeks. Furthermore, an increase in myocyte size and atrial natriuretic factor was observed in pioglitazone- compared to placebo-treated animals 4 weeks after aortic banding as well. The results of this study demonstrate that activation of PPARγ via pioglitazone does not protect the myocardium from pressure overload-induced LVH in a rat model of aortic banding. The findings rather indicate a pro-hypertrophic effect of pioglitazone treatment after aortic banding.

Keywords

Pioglitazone PPARγ Left ventricular hypertrophy Cardiac remodeling Aortic banding 

References

  1. Arakawa K, Ishihara T, Aoto M, Inamasu M, Kitamura K, Saito A (2004) An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin Exp Pharmacol Physiol 31:8–13CrossRefPubMedGoogle Scholar
  2. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H et al (2002) Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240–1246CrossRefPubMedGoogle Scholar
  3. Balakumar P, Singh M (2006) Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Methods Find Exp Clin Pharmacol 28:683–689CrossRefPubMedGoogle Scholar
  4. Bell D, McDermott BJ (2005) Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. Eur J Pharmacol 508:69–76CrossRefPubMedGoogle Scholar
  5. Bishop-Bailey D (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129:823–834CrossRefPubMedGoogle Scholar
  6. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T et al (2001) Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21:372–377PubMedGoogle Scholar
  7. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S et al (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365–371PubMedGoogle Scholar
  8. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM (2005) Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97:372–379CrossRefPubMedGoogle Scholar
  9. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM et al (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779–18789CrossRefPubMedGoogle Scholar
  10. Festuccia WT, Laplante M, Brule S, Houde VP, Achouba A et al (2009) Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. J Mol Cell Cardiol 47:85–95CrossRefPubMedGoogle Scholar
  11. Geng DF, Wu W, Jin DM, Wang JF, Wu YM (2006) Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol 113:86–91CrossRefPubMedGoogle Scholar
  12. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM et al (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46:433–439CrossRefPubMedGoogle Scholar
  13. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ et al (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547–1554CrossRefPubMedGoogle Scholar
  14. Guan Y, Hao C, Cha DR, Rao R, Lu W et al (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861–866CrossRefPubMedGoogle Scholar
  15. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A et al (2005) Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 18:949–957CrossRefPubMedGoogle Scholar
  16. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S (2004) Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 20:3108–3127CrossRefPubMedGoogle Scholar
  17. Ito H, Nakano A, Kinoshita M, Matsumori A (2003) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83:1715–1721CrossRefPubMedGoogle Scholar
  18. Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP et al (1996) Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ Res 78:517–524PubMedGoogle Scholar
  19. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566PubMedCrossRefGoogle Scholar
  20. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523–531CrossRefPubMedGoogle Scholar
  21. Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C et al (2006) The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55:622–632CrossRefPubMedGoogle Scholar
  22. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818–1820CrossRefPubMedGoogle Scholar
  23. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM et al (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108:2941–2948CrossRefPubMedGoogle Scholar
  24. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471CrossRefPubMedGoogle Scholar
  25. Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106:467–472CrossRefPubMedGoogle Scholar
  26. Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JP (1999) Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 128:1570–1576CrossRefPubMedGoogle Scholar
  27. Qayyum R, Schulman P (2006) Cardiovascular effects of the thiazolidinediones. Diabetes Metab Res Rev 22:88–97CrossRefPubMedGoogle Scholar
  28. Rangwala SM, Lazar MA (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25:331–336CrossRefPubMedGoogle Scholar
  29. Rose M, Balakumar P, Singh M (2007) Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 80:177–184CrossRefPubMedGoogle Scholar
  30. Sakai S, Miyauchi T, Irukayama-Tomobe Y, Ogata T, Goto K, Yamaguchi I (2002) Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 103(Suppl 48):16S–20SGoogle Scholar
  31. Sena S, Rasmussen IR, Wende AR, McQueen AP, Theobald HA et al (2007) Cardiac hypertrophy caused by peroxisome proliferator- activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology 148:6047–6053CrossRefPubMedGoogle Scholar
  32. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M et al (2002) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106:3126–3132CrossRefPubMedGoogle Scholar
  33. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA et al (2007) Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 117:2791–2801CrossRefPubMedGoogle Scholar
  34. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K (2001) Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104:1670–1675CrossRefPubMedGoogle Scholar
  35. Yuan Z, Liu Y, Zhang J, Kishimoto C, Wang Y et al (2003) Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis. Cardiovasc Res 59:685–694CrossRefPubMedGoogle Scholar
  36. Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A et al (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104:2588–2594CrossRefPubMedGoogle Scholar
  37. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T (2005) Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 102:9406–9411CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Celine S. Weiss
    • 1
  • Marco Hagenmüller
    • 1
  • Martina Pichler
    • 1
  • Sebastian Münz
    • 1
  • Marco Ochs
    • 1
  • Sebastian J. Buss
    • 1
  • Raffi Bekeredjian
    • 1
  • Hugo A. Katus
    • 1
  • Stefan E. Hardt
    • 1
  1. 1.Department of CardiologyUniversity Hospital HeidelbergHeidelbergGermany

Personalised recommendations